Invention Grant
US08524244B2 Targeted therapeutics based on engineered proteins that bind EGFR
有权
基于结合EGFR的工程蛋白的靶向治疗
- Patent Title: Targeted therapeutics based on engineered proteins that bind EGFR
- Patent Title (中): 基于结合EGFR的工程蛋白的靶向治疗
-
Application No.: US12867406Application Date: 2009-02-10
-
Publication No.: US08524244B2Publication Date: 2013-09-03
- Inventor: Ray Camphausen , Brent Morse , Stuart Emanuel , David Fabrizio
- Applicant: Ray Camphausen , Brent Morse , Stuart Emanuel , David Fabrizio
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Cynthia L. Kanik
- International Application: PCT/US2009/000830 WO 20090210
- International Announcement: WO2009/102421 WO 20090820
- Main IPC: A61K38/17
- IPC: A61K38/17 ; A61K38/39 ; A61K47/48 ; C07K14/71 ; C07K14/435
Abstract:
The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
Public/Granted literature
- US20110053842A1 TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR Public/Granted day:2011-03-03
Information query
IPC分类:
